Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Get full access to
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(}function setPanelState(o){dom.root.classList[o?"add":"remove"](,dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

HO/The Canadian Press

Canadian and U.S. cannabis companies are facing a spike in already high costs of insurance to protect top executives from personal liability, after a slew of lawsuits by disgruntled investors alleging fraud and misinformation, with more such action expected.

Some of the biggest cannabis companies, including Medmen Enterprises, Canopy Growth Corp., CannTrust Holdings, Aphria Inc. and Columbia Care Inc., have faced shareholder litigation, accusing leaders of false claims, failing to act in the interest of all shareholders and attempts to defraud investors.

The lawsuits are yet another sign of souring sentiment against an industry that has failed to deliver on promises of boundless growth. And the rising costs are another headwind for companies already shuttering operations and cutting jobs because of slower-than-expected demand.

Story continues below advertisement

“More frequently we’re seeing prospective investors and board members requiring [directors’ and officers’] coverage in place prior to engaging with a company in order to ensure adequate protection in the event of ... litigation,” said Charles Grodecki, senior vice-president at insurance brokerage AmWINS Brokerage of the Carolinas.

“With claims starting to roll in, we’re beginning to see higher entry-level premiums.”

Cannabis companies generated a lot of investor excitement in recent years as the drug was legalized for recreational use in Canada and 11 U.S. states, as well as the District of Columbia. Marijuana is authorized for medical use in many more.

But investors have faced losses, as well as coronavirus-driven market downturns, and they are increasingly likely to target companies and executives who have not delivered on big promises, such as cannabis firms, said Ian Stewart, partner at law firm Wilson Elser.

That could drive rates and deductibles higher, with the industry already paying well more than what non-cannabis companies pay for similar insurance products.

“We expect a flurry of cases holding directors personally liable,” Mr. Stewart said.

Avis Bulbulyan of cannabis consultancy Siva Enterprises, estimates a 50-per-cent spike in litigation.

Story continues below advertisement

A spokeswoman for Canopy declined to comment. Medmen, CannTrust, Aphria and Columbia Care did not respond to requests for comment.

The Horizons Marijuana Life Sciences Index ETF has lost 61 per cent over the past year, while the S&P 500 index is up 6 per cent.


Entry-level premiums for directors & officers (D&O) insurance for public companies have more than doubled to US$250,000 for US$1-million cover over the past year or so, on top of as much as US$1-million firms must pay before the coverage kicks in, known as retention, according to AmWINS.

Some insurers have also added exclusionary language specific to cannabis and have raised retention levels, leaving some companies unable to renew policies or forced to choose lower limits with inadequate coverage, said Katie Verry, vice-president at broker CRC Insurance Services.

Most major insurers do not offer cannabis D&O policies because cannabis is not legal under U.S. federal law and the nascent industry has increased risks.

There are even fewer insurers now, said Kirk Miller, executive producer at cannabis risk-management firm Nine Point Strategies. Insurance market Lloyd’s of London and the insurance regulator of Bermuda have prohibited insurers from underwriting cannabis coverage in the United States.

Story continues below advertisement

“With both Lloyd’s and [insurers from] Bermuda pulling out of the U.S. cannabis market, coupled with the 25+ security class-action lawsuits over the last two-and-a-half years ... underwriters’ appetite for cannabis is narrowing,” he said.

The heavy demand and a dearth of suppliers has kept prices extremely high.

A cannabis D&O policy is about three to seven times more expensive than a company in a decade-old industry, even in Canada where marijuana is federally legal, said Richard McGee, director at cannabis-focused underwriter Next Wave Insurance Canada.

Most of the lawsuits have not yet been heard in court. But a determination of intentional wrongdoing or fraud could remove legal protections against personal liability and trigger insurance exemptions, leaving companies and executives’ assets exposed.

In May, law firm Kasowitz Benson Torres LLP named Columbia Care’s founders as defendants in a lawsuit on behalf of a group of investors, accusing them of aiding and abetting in fraud.

Sarmad Khojasteh, a partner at the firm, noted by email that laws in Florida and New York do not shield corporate officers from personal liability for negligence or misconduct. Columbia Care did not respond to a request for comment.

Story continues below advertisement

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies